S. Niranjana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
S. Niranjana has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Ankur Khandelwal
Department of Anaesthesiology, Critical Care and Pain Medicine, All India Institute of Medical Sciences (AIIMS), Guwahati, Assam, India
1 shared publication - Gyaninder Pal Singh
Department of Neuroanesthesiology and Critical Care, All India Institute of Medical Sciences (AIIMS), New Delhi, India
1 shared publication - Kalyan Sarma
Department of Radiology, All India Institute of Medical Sciences (AIIMS), Guwahati, Assam, India
1 shared publication - Masaraf Hussain
Department of Neurology, All India Institute of Medical Sciences (AIIMS), Guwahati, Assam, India
1 shared publication - Priyadarshi Dikshit
Department of Neurosurgery, All India Institute of Medical Sciences (AIIMS), Guwahati, Assam, India
1 shared publication
Latest Publications
- Open Access
- 1 June 2025
- Published by Georg Thieme Verlag KG in Journal of Neuroanaesthesiology and Critical Care
- Vol. 12 (02) , 108-113
Herbal Medicines: The Double-Edged Sword for Brain—A Narrative Update
Phytochemicals or herbal medicines (HMs) with neuroprotective and nootropic properties are being increasingly utilized in various neurological conditions owing to their antioxidative, anti-inflammatory, and antiapoptotic properties, as well as their role in immune regulation, hormonal regulation, and modulation of neurotransmitters and ion channels. While HMs are often regarded as safe, they are not without risks. The aim of this review was to know the various neurological and non-neurological side effects of long-term consumption of neuroprotective and nootropic phytochemicals. An electronic search was conducted using the following databases from January 2000 to December 2023: PubMed, PubMed Central, Embase, Scopus, and Science Citation Index (Web of Science). Only studies published in the English language were considered. The search used key terms such as “Herbs,” “Phytochemicals,” “India,” “Asia,” “Neuroprotection,” “Neurological diseases,” and “Complications.” The sources included research articles, systematic reviews and meta-analyses, narrative reviews, and editorials. Letters to the editor, commentaries, abstracts only, and unpublished data were excluded. While HMs are increasingly being used therapeutically for various neurological and non-neurological conditions, they also carry the risk of adverse effects due to contamination, adulteration, direct effects of metabolites, herb–drug interactions, interindividual susceptibility, and other factors. In addition, widespread availability, over-the-counter sale, and unsupervised dosing are the key reasons for their unregulated prolonged use. As such, correct identification of HMs and consequent assessment of their toxicological profile are deemed extremely crucial. Neurotoxicity testing for HMs is challenging considering the limitations of traditional methods (morphological, microscopic, and chemical); nevertheless, in the recent years, several novel procedures have been developed. Large studies are warranted to establish the safety profile of consuming HMs either alone or in combination in humans.
- 1 June 2025
- Published by Georg Thieme Verlag KG in Journal of Neuroanaesthesiology and Critical Care
- Vol. 12 (02) , 108-113
Open AccessHerbal Medicines: The Double-Edged Sword for Brain—A Narrative Update
Phytochemicals or herbal medicines (HMs) with neuroprotective and nootropic properties are being increasingly utilized in various neurological conditions owing to their antioxidative, anti-inflammatory, and antiapoptotic properties, as well as their role in immune regulation, hormonal regulation, and modulation of neurotransmitters and ion channels. While HMs are often regarded as safe, they are not without risks. The aim of this review was to know the various neurological and non-neurological side effects of long-term consumption of neuroprotective and nootropic phytochemicals. An electronic search was conducted using the following databases from January 2000 to December 2023: PubMed, PubMed Central, Embase, Scopus, and Science Citation Index (Web of Science). Only studies published in the English language were considered. The search used key terms such as “Herbs,” “Phytochemicals,” “India,” “Asia,” “Neuroprotection,” “Neurological diseases,” and “Complications.” The sources included research articles, systematic reviews and meta-analyses, narrative reviews, and editorials. Letters to the editor, commentaries, abstracts only, and unpublished data were excluded. While HMs are increasingly being used therapeutically for various neurological and non-neurological conditions, they also carry the risk of adverse effects due to contamination, adulteration, direct effects of metabolites, herb–drug interactions, interindividual susceptibility, and other factors. In addition, widespread availability, over-the-counter sale, and unsupervised dosing are the key reasons for their unregulated prolonged use. As such, correct identification of HMs and consequent assessment of their toxicological profile are deemed extremely crucial. Neurotoxicity testing for HMs is challenging considering the limitations of traditional methods (morphological, microscopic, and chemical); nevertheless, in the recent years, several novel procedures have been developed. Large studies are warranted to establish the safety profile of consuming HMs either alone or in combination in humans.